ARD103
Near Add Your Location
Accepting patients
ARD103
A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- CAR T Cell
- Phase 1/2